CTA
BIO icon

Carillon Tower Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Carillon Tower Advisers’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,442
Closed -$582 – 457
2017
Q4 		$582 Buy
+2,442
New +$592K 0.01% 275

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carillon Tower Advisers's BIO Position: Q1 2018 in Review

Carillon Tower Advisers sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2018, closing a stake of 2,442 shares — an estimated $582 sold.

Carillon Tower Advisers first reported a position in BIO in Q4 2017 and held it in 1 quarter. The position peaked at $582 in Q4 2017. 316 funds tracked by Wall St. Rank hold BIO as of Q1 2018.

  • Carillon Tower Advisers reported no remaining Bio-Rad Laboratories Class A position as of Q1 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 2,442 Bio-Rad Laboratories Class A shares in Q1 2018, an estimated $582.
  • Carillon Tower Advisers first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 1 quarter.
  • Carillon Tower Advisers's Bio-Rad Laboratories Class A position peaked at $582 in Q4 2017.
  • 316 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2018.

Based on Carillon Tower Advisers's 13F filing for Q1 2018, filed 14 May 2018.